CHORDOMA

This study tests a new drug called BL-B01D1 in 27 people with advanced chordoma, a rare bone cancer that has spread or cannot be removed by surgery. The main goal is to see if the drug can shrink tumors. Participants receive the drug and are monitored for safety and how long the …

This study tests two immunotherapy drugs, nivolumab and ipilimumab, in adults with over 50 types of rare cancers. The goal is to see if this drug combination can shrink tumors or stop them from growing. The trial is no longer enrolling new participants, but results will help guid…

This study tests a combination of three drugs (tazemetostat, nivolumab, and ipilimumab) for children with rare tumors that lack certain proteins (INI1 or SMARCA4). The goal is to find a safe dose and see if the drugs can shrink tumors. About 49 children with specific cancers like…

This study tests a new drug called ERAS-601 in people with advanced chordoma, a rare bone cancer. The goal is to see if the drug is safe and can stop or shrink tumors. About 12 adults whose cancer has gotten worse despite prior treatment will take part.

This early-stage study tests the safety of combining an immunotherapy drug (nivolumab) with or without precise radiation (stereotactic radiosurgery) in 21 people with chordoma that has returned or spread. The goal is to see if this combination is safe and tolerable. Participants …

This study tests whether proton beam therapy, sometimes combined with standard radiation, can control skull base chordoma—a rare tumor near the brain. Nineteen adults who had surgery to remove most of the tumor will receive this precise radiation. Researchers will track tumor rec…

This study tests a drug called cetuximab in 29 adults with advanced or metastatic chordoma, a rare bone cancer. The goal is to see if cetuximab can shrink tumors or stop them from growing. Participants receive the drug intravenously and are monitored for response and side effects…

This study follows 400 adults who had skull base surgery through the nose. Researchers will measure quality of life and nose function for 2 years after surgery. The goal is to understand how modern surgical techniques affect long-term recovery and daily living.